Identification

Name
Dimenhydrinate
Accession Number
DB00985  (APRD00924)
Type
Small Molecule
Groups
Approved
Description

Dimenhydrinate, also known as Dramamine or Gravol, is an over-the-counter drug used to prevent nausea, vomiting, and dizziness caused by motion sickness. Dimenhydrinate is a combination drug composed of Diphenhydramine and 8-chlorotheophylline in a salt form, with 53%-55.5% of diphenhydramine, and not less than 44%-47% of 8-chlorotheophylline, calculated on the dried basis.

The antiemetic properties of dimenhydrinate are primarily thought to be produced by diphenhydramine's antagonism of H1 histamine receptors in the vestibular system [3] while the excitatory effects are thought to be produced by 8-chlorotheophylline's adenosine receptor blockade [4]. The addition of 8-chlorotheophylline was initially intended to counteract the sedative effects of diphenhydramine.

When used in large doses, dimenhydrinate has been shown to cause a "high" characterized by hallucinations, excitement, incoordination, and disorientation [2].

Structure
Thumb
Synonyms
  • (O-Benzhydryl(dimethylamino)ethanol) 8-chlorotheophyllinate
  • 8-chloro-1,3-Dimethyl-3,7-dihydro-1H-purine-2,6-dione - 2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1)
  • Benzhydryl-beta-dimethylaminoethylether 8-chlorotheophylline
  • beta-Dimethylaminoethyl benzhydryl ether 1,3-dimethyl-8-chloroxanthine
  • Dimenhidrinato
  • Dimenhydrinatum
  • Diphenhydramine 8-chlorotheophyllinate
  • Diphenhydramine 8-chlorotheophylline
  • Diphenhydramine theoclate
  • Diphenhydrinate
  • N,N-Dimethyl-2-diphenylmethoxyethylamine 8-chlorotheophyllinate
  • O-Benzhydryldimethylaminoethanol 8-chlorotheophyllinate
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dimenhydrinate Inj 10mgLiquid10 mgIntravenousSandoz Canada Incorporated1973-12-31Not applicableCanada
Dimenhydrinate Inj 10mg/mlLiquid10 mgIntravenousAstra Pharma Inc.1986-12-311999-07-29Canada
Dimenhydrinate Inj 50mg USPLiquid50 mgIntramuscular; IntravenousSandoz Canada Incorporated1973-12-31Not applicableCanada
Dimenhydrinate Injection 50mg/mlSolution50 mgIntramuscular; IntravenousAstra Zeneca1986-12-312005-05-31Canada
Dimenhydrinate Injection USPSolution50 mgIntramuscular; IntravenousTeligent Ou2016-01-28Not applicableCanada
Dimenhydrinate Injection USP 250mg/5ml (50mg/ml)Solution50 mgIntramuscular; IntravenousAlveda Pharmaceuticals Inc2008-06-26Not applicableCanada
Dimenhydrinate Injection USP With PreservativeSolution50 mgIntramuscular; IntravenousTeligent Ou2016-01-28Not applicableCanada
Dimenhydrinate Injection, USPSolution50 mgIntramuscular; IntravenousMylan Pharmaceuticals1994-12-31Not applicableCanada
Gravol ImSolution50 mgIntramuscularChurch & Dwight Company, Inc.1953-12-31Not applicableCanada
Gravol IV AmpoulesSolution10 mgIntravenousChurch & Dwight Company, Inc.1953-12-312008-07-30Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DimenhydrinateInjection, solution50 mg/mLIntramuscular; IntravenousAPP Pharmaceuticals, Inc.2004-11-29Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Airmit AceTablet25 mg/1OralSato Pharmaceutical2005-03-11Not applicableUs
Anti-nauseantTablet50 mgOralPharmascience Inc2002-08-23Not applicableCanada
Anti-nauseantTablet50 mgOralApotex Corporation2013-07-02Not applicableCanada
Anti-nauseantTablet50 mgOralTevaNot applicableNot applicableCanada
Anti-nauseantTablet50 mgOralPharmascience IncNot applicableNot applicableCanada
Anti-nauseantTablet50 mgOralVita Health Products Inc2000-05-01Not applicableCanada
Anti-nauseant TabletTablet50 mgOralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1998-05-262008-08-07Canada
Apo Dimenhydrinate Tab 50mgTablet50 mgOralApotex Corporation1977-12-31Not applicableCanada
Children's Motion Sickness LiqSolution15 mgOralTanta Pharmaceuticals Inc1996-12-31Not applicableCanada
Children's Motion Sickness LiquidSolution15 mgOralAra Avanti Rx Analytics IncNot applicableNot applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Gravergol CapsulesDimenhydrinate (50 mg) + Caffeine (100 mg) + Ergotamine tartrate (1 mg)CapsuleOralCan Med Pharma Inc.1957-12-312011-12-07Canada
International/Other Brands
Gravol (Church & Dwight) / Vertirosan (Astellas) / Vomex A (Astellas) / Xamamina (Adilna)
Categories
UNII
JB937PER5C
CAS number
523-87-5
Weight
Average: 469.964
Monoisotopic: 469.188067494
Chemical Formula
C24H28ClN5O3
InChI Key
DKHVTDUUNTVKOW-UHFFFAOYSA-N
InChI
InChI=1S/C17H21NO.C7H7ClN4O2/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16;1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14/h3-12,17H,13-14H2,1-2H3;1-2H3,(H,9,10,13)
IUPAC Name
8-chloro-1,3-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-7-ide; [2-(diphenylmethoxy)ethyl]dimethylazanium
SMILES
CN1C2=C([N-]C(Cl)=N2)C(=O)N(C)C1=O.C[NH+](C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1

Pharmacology

Indication

Dimenhydrinate is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness.

Associated Conditions
Pharmacodynamics

Dimenhydrinate is an antiemetics drug combination that contains diphenhydramine and theophylline. It is not effective in the treatment of nausea associated with cancer chemotherapy. Dimenhydrinate directly inhibits the stimulation of certain nerves in the brain and inner ear to suppress nausea, vomiting, dizziness, and vertigo. Diphenhydramine and dimenhydinate both reduce vestibular neuronal excitation due to angular or linear acceleration motions.

Mechanism of action

The mechanism by which some antihistamines exert their antiemetic, anti-motion sickness, and anti-vertigo effects is not precisely known but may be related to their central anticholinergic actions. They diminish vestibular stimulation and depress labyrinthine function. An action on the medullary chemoreceptive trigger zone may also be involved in the antiemetic effect. Dimenhydrinate is a competitive antagonist at the histamine H1 receptor, which is widely distributed in the human brain. Dimenhydrinate's anti-emetic effect is probably due to H1 antagonism in the vestibular system in the brain.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
Absorption

Well absorbed after oral administration.

Volume of distribution
Not Available
Protein binding

98 to 99%.

Metabolism

Hepatic (cytochrome P-450 system).

Route of elimination
Not Available
Half life

1 to 4 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include delerium, hallucinations, and excitment. Patients may be violent and confused.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative and stimulatory activities of Dimenhydrinate.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative and stimulatory activities of Dimenhydrinate.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative and stimulatory activities of Dimenhydrinate.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative and stimulatory activities of Dimenhydrinate.Experimental, Illicit
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with 4-Methoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with 5-methoxy-N,N-dimethyltryptamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AbexinostatThe risk or severity of QTc prolongation can be increased when Abexinostat is combined with Dimenhydrinate.Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Dimenhydrinate.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Acetophenazine.Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Acetylglycinamide chloral hydrate.Experimental
AcrivastineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Dimenhydrinate.Approved
AdinazolamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Adinazolam.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Alaproclate.Experimental
AlcaftadineThe risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Dimenhydrinate.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Alcuronium.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Dimenhydrinate.Approved, Illicit
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Dimenhydrinate.Approved, Investigational
AlimemazineThe risk or severity of QTc prolongation can be increased when Alimemazine is combined with Dimenhydrinate.Approved, Vet Approved
AllobarbitalThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Allobarbital.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Almotriptan.Approved, Investigational
AlosetronThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Alosetron.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dimenhydrinate.Approved, Illicit, Investigational
AlprenololThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Alprenolol.Approved, Withdrawn
AlverineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Alverine.Approved, Investigational
AmantadineThe risk or severity of QTc prolongation can be increased when Amantadine is combined with Dimenhydrinate.Approved
AmifampridineThe risk or severity of QTc prolongation can be increased when Amifampridine is combined with Dimenhydrinate.Approved
AmikacinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Amikacin.Approved, Investigational, Vet Approved
AmineptineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Amineptine.Illicit, Withdrawn
AmiodaroneThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Dimenhydrinate.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Amitriptylinoxide.Approved, Investigational
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dimenhydrinate.Approved, Illicit
AmodiaquineThe risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Dimenhydrinate.Approved, Investigational
AmoxapineThe risk or severity of QTc prolongation can be increased when Amoxapine is combined with Dimenhydrinate.Approved
AmperozideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Amperozide.Experimental
AmphetamineAmphetamine may decrease the sedative and stimulatory activities of Dimenhydrinate.Approved, Illicit, Investigational
AnagrelideThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Anagrelide.Approved
AniracetamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Aniracetam.Experimental
AntazolineThe risk or severity of QTc prolongation can be increased when Antazoline is combined with Dimenhydrinate.Approved
APD791The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with APD791.Investigational
ApomorphineThe risk or severity of QTc prolongation can be increased when Apomorphine is combined with Dimenhydrinate.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Apramycin.Experimental, Vet Approved
AprobarbitalThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Aprobarbital.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Apronalide.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Arbaclofen Placarbil.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Arbekacin.Approved, Investigational
ArformoterolThe risk or severity of QTc prolongation can be increased when Arformoterol is combined with Dimenhydrinate.Approved, Investigational
AripiprazoleThe risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Dimenhydrinate.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Dimenhydrinate.Approved, Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Artemether.Approved
AsenapineThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Asenapine.Approved
AstemizoleThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Astemizole.Approved, Withdrawn
AtazanavirThe risk or severity of QTc prolongation can be increased when Atazanavir is combined with Dimenhydrinate.Approved, Investigational
AtomoxetineThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Dimenhydrinate.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Atracurium.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Atracurium besylate.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Azaperone.Investigational, Vet Approved
AzatadineThe risk or severity of QTc prolongation can be increased when Azatadine is combined with Dimenhydrinate.Approved
AZD-3043The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with AZD-3043.Investigational
AzelastineDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinThe risk or severity of QTc prolongation can be increased when Azithromycin is combined with Dimenhydrinate.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Dimenhydrinate.Approved
BarbexacloneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Barbexaclone.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Barbital.Illicit
BeclamideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Beclamide.Experimental
BedaquilineThe risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Dimenhydrinate.Approved
BekanamycinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Bekanamycin.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Benactyzine.Withdrawn
BenmoxinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Benperidol.Approved, Investigational
BenzatropineThe risk or severity of QTc prolongation can be increased when Benzatropine is combined with Dimenhydrinate.Approved
BenzoctamineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Benzoctamine.Approved
BenzphetamineBenzphetamine may decrease the sedative and stimulatory activities of Dimenhydrinate.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineDimenhydrinate may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Bepridil.Approved, Withdrawn
BesifloxacinThe risk or severity of QTc prolongation can be increased when Besifloxacin is combined with Dimenhydrinate.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Dimenhydrinate.Approved, Investigational
BifemelaneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Bifemelane.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Bifeprunox.Investigational
BilastineThe risk or severity of QTc prolongation can be increased when Bilastine is combined with Dimenhydrinate.Approved, Investigational
BL-1020The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with BL-1020.Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Blonanserin.Approved, Investigational
BortezomibThe risk or severity of QTc prolongation can be increased when Bortezomib is combined with Dimenhydrinate.Approved, Investigational
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Botulinum Toxin Type B.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved
BrivaracetamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Brivaracetam.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dimenhydrinate.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Dimenhydrinate.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Brotizolam.Approved, Investigational, Withdrawn
BuclizineThe risk or severity of QTc prolongation can be increased when Buclizine is combined with Dimenhydrinate.Approved
BufotenineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Bufotenine.Experimental, Illicit
BuprenorphineDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Bupropion.Approved
BuserelinThe risk or severity of QTc prolongation can be increased when Buserelin is combined with Dimenhydrinate.Approved, Investigational
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dimenhydrinate.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dimenhydrinate.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Dimenhydrinate.Approved, Illicit
ButaperazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dimenhydrinate.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of QTc prolongation can be increased when Butriptyline is combined with Dimenhydrinate.Approved
CabergolineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Cabergoline.Approved
CamazepamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Camazepam.Approved, Illicit
CannabidiolThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Cannabidiol.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Cannabidivarin.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Capreomycin.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Captodiame.Approved, Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dimenhydrinate.Approved, Investigational
CarbinoxamineThe risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Dimenhydrinate.Approved
CarbromalThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Carbromal.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Cariprazine.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Carisbamate.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dimenhydrinate.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Caroxazone.Withdrawn
CathinoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Cathinone.Illicit
CeritinibThe risk or severity of QTc prolongation can be increased when Ceritinib is combined with Dimenhydrinate.Approved
CerlapirdineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Cerlapirdine.Investigational
CetirizineThe risk or severity of QTc prolongation can be increased when Cetirizine is combined with Dimenhydrinate.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlorcyclizineThe risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Dimenhydrinate.Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dimenhydrinate.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroquineThe risk or severity of QTc prolongation can be increased when Chloroquine is combined with Dimenhydrinate.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Dimenhydrinate.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorphentermineChlorphentermine may decrease the sedative and stimulatory activities of Dimenhydrinate.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Dimenhydrinate.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Dimenhydrinate.Approved, Investigational, Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Chlortetracycline.Approved, Investigational, Vet Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dimenhydrinate.Approved
CilansetronThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Cilansetron.Investigational
CilostazolThe risk or severity of QTc prolongation can be increased when Cilostazol is combined with Dimenhydrinate.Approved, Investigational
CinitaprideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Cinitapride.Approved, Investigational
CinnarizineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Dimenhydrinate.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Cinolazepam.Approved
CinoxacinThe risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Dimenhydrinate.Approved, Investigational, Withdrawn
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Dimenhydrinate.Approved, Investigational
CisaprideThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Cisatracurium.Approved
CitalopramThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Citalopram.Approved
ClarithromycinThe risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Dimenhydrinate.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Dimenhydrinate.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Dimenhydrinate.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of QTc prolongation can be increased when Clomipramine is combined with Dimenhydrinate.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Clomocycline.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Dimenhydrinate.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dimenhydrinate.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Clothiapine.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Clotiazepam.Approved, Illicit
CloxazolamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Cloxazolam.Approved, Investigational
ClozapineThe risk or severity of QTc prolongation can be increased when Clozapine is combined with Dimenhydrinate.Approved
CocaineThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dimenhydrinate.Approved, Illicit
ColistimethateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Colistimethate.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Colistin.Approved
CrizotinibThe risk or severity of QTc prolongation can be increased when Crizotinib is combined with Dimenhydrinate.Approved
CUDC-101The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Dimenhydrinate.Investigational
CUDC-907The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Dimenhydrinate.Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Cyamemazine.Approved
CyclizineThe risk or severity of QTc prolongation can be increased when Cyclizine is combined with Dimenhydrinate.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Cyclobarbital.Experimental
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dimenhydrinate.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Cyclopropane.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Dimenhydrinate.Approved
DabrafenibThe risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Dimenhydrinate.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dapoxetine.Investigational
DasatinibThe risk or severity of QTc prolongation can be increased when Dasatinib is combined with Dimenhydrinate.Approved, Investigational
DeanolThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Deanol.Experimental
DecamethoniumThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Decamethonium.Approved
DegarelixThe risk or severity of QTc prolongation can be increased when Degarelix is combined with Dimenhydrinate.Approved
DelamanidThe risk or severity of QTc prolongation can be increased when Delamanid is combined with Dimenhydrinate.Approved, Investigational
DelorazepamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Delorazepam.Approved, Illicit, Investigational
DemeclocyclineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Demeclocycline.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of QTc prolongation can be increased when Desflurane is combined with Dimenhydrinate.Approved
DesipramineThe risk or severity of QTc prolongation can be increased when Desipramine is combined with Dimenhydrinate.Approved, Investigational
DesloratadineThe risk or severity of QTc prolongation can be increased when Desloratadine is combined with Dimenhydrinate.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Dimenhydrinate.Approved
DexchlorpheniramineThe risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Dimenhydrinate.Experimental, Investigational
Dexchlorpheniramine maleateThe risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Dimenhydrinate.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dexmethylphenidate.Approved, Investigational
DextofisopamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dextofisopam.Investigational
DextroamphetamineDextroamphetamine may decrease the sedative and stimulatory activities of Dimenhydrinate.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Dimenhydrinate.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dibekacin.Experimental
DibenzepinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dibenzepin.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dichloralphenazone.Approved, Illicit
Diethyl etherThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may decrease the sedative and stimulatory activities of Dimenhydrinate.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Difenoxin.Approved, Illicit
DifloxacinThe risk or severity of QTc prolongation can be increased when Difloxacin is combined with Dimenhydrinate.Vet Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dimenhydrinate.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dihydrostreptomycin.Investigational, Vet Approved
DimetacrineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dimetacrine.Approved, Withdrawn
DimethyltryptamineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dimethyltryptamine.Experimental, Illicit
DiphenhydramineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Dimenhydrinate.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dimenhydrinate.Approved, Illicit
DisopyramideThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dixyrazine.Experimental
DofetilideThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Dofetilide.Approved, Investigational
DolasetronThe risk or severity of QTc prolongation can be increased when Dolasetron is combined with Dimenhydrinate.Approved, Investigational
Domoic AcidThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Domoic Acid.Experimental
DomperidoneThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Domperidone.Approved, Investigational, Vet Approved
DonepezilThe risk or severity of QTc prolongation can be increased when Donepezil is combined with Dimenhydrinate.Approved
DopamineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dopamine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Doramectin.Vet Approved
DosulepinThe risk or severity of QTc prolongation can be increased when Dosulepin is combined with Dimenhydrinate.Approved
DotarizineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dotarizine.Investigational
DoxacuriumThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Doxacurium.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Doxefazepam.Experimental
DoxepinThe risk or severity of QTc prolongation can be increased when Doxepin is combined with Dimenhydrinate.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved, Illicit
DronedaroneThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dyclonine.Approved
EbastineThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Dimenhydrinate.Approved, Investigational
EcopipamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ecopipam.Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Edivoxetine.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Dimenhydrinate.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Eletriptan.Approved, Investigational
EliglustatThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Eltanolone.Investigational
EltoprazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Eltoprazine.Investigational
EmedastineThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Emedastine.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Emepronium.Experimental
EmylcamateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Emylcamate.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Enflurane.Approved, Investigational, Vet Approved
EnoxacinThe risk or severity of QTc prolongation can be increased when Enoxacin is combined with Dimenhydrinate.Approved, Investigational
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Dimenhydrinate.Approved, Investigational
EntinostatThe risk or severity of QTc prolongation can be increased when Entinostat is combined with Dimenhydrinate.Investigational
EperisoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Eperisone.Approved, Investigational
EpinastineThe risk or severity of QTc prolongation can be increased when Epinastine is combined with Dimenhydrinate.Approved, Investigational
EplivanserinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Eplivanserin.Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ergotamine.Approved
EribulinThe risk or severity of QTc prolongation can be increased when Eribulin is combined with Dimenhydrinate.Approved, Investigational
ErlotinibThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Erlotinib.Approved, Investigational
ErythromycinThe risk or severity of QTc prolongation can be increased when Erythromycin is combined with Dimenhydrinate.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Escitalopram.Approved, Investigational
EslicarbazepineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Eslicarbazepine.Approved
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Esmirtazapine.Investigational
EsreboxetineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Esreboxetine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Dimenhydrinate.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dimenhydrinate.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Etacrynic acid.Approved, Investigational
EthadioneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ethadione.Experimental
EthanolDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dimenhydrinate.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Dimenhydrinate.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ethylmorphine.Approved, Illicit
EtifoxineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Etifoxine.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Etiracetam.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of QTc prolongation can be increased when Ezogabine is combined with Dimenhydrinate.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Fabomotizole.Experimental
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Dimenhydrinate.Approved
Fazadinium bromideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Fazadinium bromide.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Febarbamate.Experimental
FelbamateThe risk or severity of QTc prolongation can be increased when Felbamate is combined with Dimenhydrinate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dimenhydrinate.Approved, Illicit, Investigational, Vet Approved
FenyramidolThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Fenyramidol.Experimental
FexofenadineThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Fexofenadine.Approved, Investigational
FingolimodThe risk or severity of QTc prolongation can be increased when Fingolimod is combined with Dimenhydrinate.Approved, Investigational
FlecainideThe risk or severity of QTc prolongation can be increased when Flecainide is combined with Dimenhydrinate.Approved, Withdrawn
FleroxacinThe risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Dimenhydrinate.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Fluanisone.Experimental
FluconazoleThe risk or severity of QTc prolongation can be increased when Fluconazole is combined with Dimenhydrinate.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Fludiazepam.Approved, Illicit
FlumequineThe risk or severity of QTc prolongation can be increased when Flumequine is combined with Dimenhydrinate.Withdrawn
FlunarizineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dimenhydrinate.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dimenhydrinate.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Dimenhydrinate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Fluvoxamine.Approved, Investigational
FormoterolThe risk or severity of QTc prolongation can be increased when Formoterol is combined with Dimenhydrinate.Approved, Investigational
FoscarnetThe risk or severity of QTc prolongation can be increased when Foscarnet is combined with Dimenhydrinate.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Fospropofol.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Framycetin.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Frovatriptan.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Furazolidone.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dimenhydrinate.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Gabapentin Enacarbil.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Gaboxadol.Investigational
Gadobenic acidThe risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Dimenhydrinate.Approved, Investigational
GalantamineThe risk or severity of QTc prolongation can be increased when Galantamine is combined with Dimenhydrinate.Approved
GallamineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Gallamine Triethiodide.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dimenhydrinate.Approved, Illicit, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Gantacurium Chloride.Investigational
GarenoxacinThe risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Dimenhydrinate.Investigational
GatifloxacinThe risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Dimenhydrinate.Approved, Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Gedocarnil.Experimental
GemifloxacinThe risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Dimenhydrinate.Approved, Investigational
GeneticinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with GENTAMICIN C1A.Experimental
GepefrineGepefrine may decrease the sedative and stimulatory activities of Dimenhydrinate.Experimental
GepironeThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Gepirone.Investigational
GivinostatThe risk or severity of QTc prolongation can be increased when Givinostat is combined with Dimenhydrinate.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Glutethimide.Approved, Illicit
GoserelinThe risk or severity of QTc prolongation can be increased when Goserelin is combined with Dimenhydrinate.Approved
GranisetronThe risk or severity of QTc prolongation can be increased when Granisetron is combined with Dimenhydrinate.Approved, Investigational
GrepafloxacinThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Grepafloxacin.Approved, Investigational, Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Halofantrine.Approved
HaloperidolThe risk or severity of QTc prolongation can be increased when Haloperidol is combined with Dimenhydrinate.Approved
HalothaneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Harmaline.Experimental
HeptabarbitalThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Heptabarbital.Approved
HeroinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Heroin.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Hexafluronium.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Hexapropymate.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Hexobarbital.Approved
HistrelinThe risk or severity of QTc prolongation can be increased when Histrelin is combined with Dimenhydrinate.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dimenhydrinate.Approved, Investigational
HydracarbazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Hydracarbazine.Experimental
HydrocodoneDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dimenhydrinate.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative and stimulatory activities of Dimenhydrinate.Approved
HydroxychloroquineThe risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Dimenhydrinate.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Hygromycin B.Vet Approved
HypericinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Hypericin.Investigational
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dimenhydrinate.Approved, Investigational
IbutilideThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Ibutilide.Approved
IdalopirdineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Idalopirdine.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ifenprodil.Approved, Investigational, Withdrawn
IferanserinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Iferanserin.Investigational
IloperidoneThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Iloperidone.Approved
ImagabalinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Imagabalin.Investigational
ImatinibThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Imatinib.Approved
ImipramineThe risk or severity of QTc prolongation can be increased when Imipramine is combined with Dimenhydrinate.Approved
Imipramine oxideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Imipramine oxide.Experimental
IndacaterolThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Dimenhydrinate.Approved
IndalpineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of QTc prolongation can be increased when Indapamide is combined with Dimenhydrinate.Approved
IndiplonThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Indiplon.Investigational
Iofetamine I-123Iofetamine I-123 may decrease the sedative and stimulatory activities of Dimenhydrinate.Approved
IprazochromeThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Iprazochrome.Experimental
IprindoleThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Iprindole.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Iproniazid.Withdrawn
IsepamicinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Isepamicin.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of QTc prolongation can be increased when Isoflurane is combined with Dimenhydrinate.Approved, Vet Approved
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Dimenhydrinate.Approved, Investigational
ItraconazoleThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Dimenhydrinate.Approved, Investigational
IvabradineThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Ivabradine.Approved
IvosidenibThe risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Dimenhydrinate.Approved, Investigational
KanamycinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Kanamycin.Approved, Investigational, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dimenhydrinate.Approved, Vet Approved
KetanserinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Dimenhydrinate.Approved, Investigational
KetotifenThe risk or severity of QTc prolongation can be increased when Ketotifen is combined with Dimenhydrinate.Approved
L-TryptophanThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with L-Tryptophan.Approved, Nutraceutical, Withdrawn
LacosamideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Lacosamide.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dimenhydrinate.Approved, Investigational
LanicemineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Lanicemine.Investigational
LapatinibThe risk or severity of QTc prolongation can be increased when Lapatinib is combined with Dimenhydrinate.Approved, Investigational
LasmiditanThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Lasmiditan.Investigational
LenvatinibThe risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Dimenhydrinate.Approved, Investigational
LeuprolideThe risk or severity of QTc prolongation can be increased when Leuprolide is combined with Dimenhydrinate.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Levetiracetam.Approved, Investigational
LevocabastineThe risk or severity of QTc prolongation can be increased when Levocabastine is combined with Dimenhydrinate.Approved, Investigational
LevocetirizineThe risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Dimenhydrinate.Approved
LevodopaThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Levodopa.Approved
LevofloxacinThe risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Dimenhydrinate.Approved, Investigational
Levomethadyl AcetateThe risk or severity of QTc prolongation can be increased when Levomethadyl Acetate is combined with Dimenhydrinate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dimenhydrinate.Approved
LincomycinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Lincomycin.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Linezolid.Approved, Investigational
LisdexamfetamineLisdexamfetamine may decrease the sedative and stimulatory activities of Dimenhydrinate.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Lisuride.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Lithium carbonate.Approved
Lithium cationThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Lithium cation.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Lofentanil.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Lofepramine.Experimental
LofexidineThe therapeutic efficacy of Dimenhydrinate can be increased when used in combination with Lofexidine.Approved, Investigational
LomefloxacinThe risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Dimenhydrinate.Approved, Investigational
LopinavirThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Loprazolam.Experimental
LoratadineThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dimenhydrinate.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Lormetazepam.Approved
LorpiprazoleThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Lorpiprazole.Approved
LortalamineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Lortalamine.Experimental
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dimenhydrinate.Approved
LumateperoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Lumateperone.Investigational
LumefantrineThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dimenhydrinate.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Lymecycline.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Lysergic Acid Diethylamide.Illicit, Investigational, Withdrawn
m-ChlorophenylpiperazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with m-Chlorophenylpiperazine.Investigational
MacimorelinThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Macimorelin.Approved, Investigational
Magnesium acetateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Magnesium acetate.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Magnesium acetate tetrahydrate.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Magnesium Aluminum Silicate.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Magnesium aspartate.Experimental
Magnesium carbonateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Magnesium carbonate.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Magnesium cation.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Magnesium chloride.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Magnesium citrate.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Magnesium gluconate.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Magnesium glycinate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Magnesium hydroxide.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Magnesium orotate.Experimental
Magnesium oxideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Magnesium oxide.Approved
Magnesium phosphateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Magnesium phosphate.Experimental
Magnesium silicateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Magnesium silicate.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Magnesium stearate.Investigational
Magnesium sulfateThe therapeutic efficacy of Dimenhydrinate can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Magnesium Trisilicate.Approved
MaprotilineThe risk or severity of QTc prolongation can be increased when Maprotiline is combined with Dimenhydrinate.Approved, Investigational
MazindolThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Mazindol.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Mebicar.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Mebutamate.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Dimenhydrinate.Approved
MedazepamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Medetomidine.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Medifoxamine.Experimental
MefloquineThe risk or severity of QTc prolongation can be increased when Mefloquine is combined with Dimenhydrinate.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Melitracen.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Melperone.Approved, Investigational
MephedroneMephedrone may decrease the sedative and stimulatory activities of Dimenhydrinate.Investigational
MephenesinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Mephenesin.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Mephenoxalone.Experimental
MephentermineMephentermine may decrease the sedative and stimulatory activities of Dimenhydrinate.Approved
MephenytoinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Mephenytoin.Investigational, Withdrawn
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dimenhydrinate.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Meptazinol.Experimental
MepyramineThe risk or severity of QTc prolongation can be increased when Mepyramine is combined with Dimenhydrinate.Approved, Vet Approved
MequitazineThe risk or severity of QTc prolongation can be increased when Mequitazine is combined with Dimenhydrinate.Approved
MesoridazineThe risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Dimenhydrinate.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dimenhydrinate.Approved
MetergolineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Metergoline.Experimental
MethacyclineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Methacycline.Approved, Investigational
MethadoneThe risk or severity of QTc prolongation can be increased when Methadone is combined with Dimenhydrinate.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative and stimulatory activities of Dimenhydrinate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Methaqualone.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Metharbital.Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dimenhydrinate.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dimenhydrinate.Approved
MethotrimeprazineDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative and stimulatory activities of Dimenhydrinate.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Methsuximide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Methylene blue.Approved, Investigational
MethylpentynolThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Methylpentynol.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Methylphenobarbital.Approved
MethyprylonThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Methyprylon.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Methysergide.Approved
MetoclopramideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Dimenhydrinate.Approved, Investigational
MetocurineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Metocurine.Approved
Metocurine IodideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Metocurine Iodide.Approved, Withdrawn
MetronidazoleThe risk or severity of QTc prolongation can be increased when Metronidazole is combined with Dimenhydrinate.Approved
MetyrosineDimenhydrinate may increase the sedative activities of Metyrosine.Approved
MianserinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Mianserin.Approved, Investigational
MicronomicinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Micronomicin.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Dimenhydrinate.Approved, Illicit
MidomafetamineMidomafetamine may decrease the sedative and stimulatory activities of Dimenhydrinate.Experimental, Illicit, Investigational
MifepristoneThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Milnacipran.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved, Investigational
MirabegronThe risk or severity of QTc prolongation can be increased when Mirabegron is combined with Dimenhydrinate.Approved
MirtazapineDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MivacuriumThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Mivacurium.Approved
MK-212The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with MK-212.Investigational
MMDAMMDA may decrease the sedative and stimulatory activities of Dimenhydrinate.Experimental, Illicit
MocetinostatThe risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Dimenhydrinate.Investigational
MoclobemideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Moclobemide.Approved, Investigational
MoexiprilThe risk or severity of QTc prolongation can be increased when Moexipril is combined with Dimenhydrinate.Approved
MolindoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Moricizine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dimenhydrinate.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Mosapramine.Experimental
MosaprideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Mosapride.Investigational
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Dimenhydrinate.Approved, Investigational
MRK-409The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with MRK-409.Experimental
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved, Investigational
NaftidrofurylThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Naftidrofuryl.Experimental
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dimenhydrinate.Approved
Nalidixic AcidThe risk or severity of QTc prolongation can be increased when Nalidixic Acid is combined with Dimenhydrinate.Approved, Investigational
NaluzotanThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Naluzotan.Investigational
NaratriptanThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Naratriptan.Approved, Investigational
NaronaprideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Naronapride.Investigational
NeamineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Neamine.Experimental
NefazodoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Nefiracetam.Investigational
NelfinavirThe risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Dimenhydrinate.Approved
NemonoxacinThe risk or severity of QTc prolongation can be increased when Nemonoxacin is combined with Dimenhydrinate.Investigational
NeocitrullamonThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Neocitrullamon.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Neosaxitoxin.Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Netilmicin.Approved, Investigational
NialamideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Nialamide.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Niaprazine.Experimental
NicardipineThe risk or severity of QTc prolongation can be increased when Nicardipine is combined with Dimenhydrinate.Approved, Investigational
NilotinibThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Nilotinib.Approved, Investigational
NisoxetineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Nisoxetine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dimenhydrinate.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Dimenhydrinate.Approved, Vet Approved
NomifensineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Nomifensine.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Nordazepam.Approved
NorfloxacinThe risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Dimenhydrinate.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Dimenhydrinate.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Octamoxin.Withdrawn
OctreotideThe risk or severity of QTc prolongation can be increased when Octreotide is combined with Dimenhydrinate.Approved, Investigational
OfloxacinThe risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Dimenhydrinate.Approved
OlanzapineThe risk or severity of QTc prolongation can be increased when Olanzapine is combined with Dimenhydrinate.Approved, Investigational
OlodaterolThe risk or severity of QTc prolongation can be increased when Olodaterol is combined with Dimenhydrinate.Approved
OlopatadineThe risk or severity of QTc prolongation can be increased when Olopatadine is combined with Dimenhydrinate.Approved
OndansetronThe risk or severity of QTc prolongation can be increased when Ondansetron is combined with Dimenhydrinate.Approved
OpipramolThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Opium.Approved, Illicit
OrbifloxacinThe risk or severity of QTc prolongation can be increased when Orbifloxacin is combined with Dimenhydrinate.Vet Approved
OrphenadrineDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Orvepitant.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Osanetant.Investigational
OxaflozaneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Oxaflozane.Experimental
OxaliplatinThe risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Dimenhydrinate.Approved, Investigational
OxaprotilineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Oxaprotiline.Experimental
OxatomideThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Oxatomide.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dimenhydrinate.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Oxcarbazepine.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Oxiracetam.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Oxitriptan.Approved, Investigational, Nutraceutical
Oxolinic acidThe risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Dimenhydrinate.Experimental
OxprenololThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dimenhydrinate.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dimenhydrinate.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Oxypertine.Experimental
OxytetracyclineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Oxytetracycline.Approved, Investigational, Vet Approved
OxytocinThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dimenhydrinate.Approved, Vet Approved
PaliperidoneThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Paliperidone.Approved
PalonosetronThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Palonosetron.Approved, Investigational
PancuroniumThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pancuronium.Approved
PanobinostatThe risk or severity of QTc prolongation can be increased when Panobinostat is combined with Dimenhydrinate.Approved, Investigational
PapaverineThe risk or severity of QTc prolongation can be increased when Papaverine is combined with Dimenhydrinate.Approved, Investigational
ParaldehydeDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Paramethadione.Approved
PargylineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pargyline.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Paroxetine.Approved, Investigational
PasireotideThe risk or severity of QTc prolongation can be increased when Pasireotide is combined with Dimenhydrinate.Approved
PazopanibThe risk or severity of QTc prolongation can be increased when Pazopanib is combined with Dimenhydrinate.Approved
PazufloxacinThe risk or severity of QTc prolongation can be increased when Pazufloxacin is combined with Dimenhydrinate.Investigational
PefloxacinThe risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Dimenhydrinate.Approved
PenbutololThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Penfluridol.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Penimepicycline.Experimental
PentamidineThe risk or severity of QTc prolongation can be increased when Pentamidine is combined with Dimenhydrinate.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dimenhydrinate.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dimenhydrinate.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved
PerazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Perazine.Approved, Investigational
PerflutrenThe risk or severity of QTc prolongation can be increased when Perflutren is combined with Dimenhydrinate.Approved
PergolideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dimenhydrinate.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dimenhydrinate.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Phenacemide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Phenazocine.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Phencyclidine.Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Phenelzine.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Phenethylamine.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pheneturide.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pheniprazine.Withdrawn
PheniramineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Dimenhydrinate.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dimenhydrinate.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Phenoperidine.Experimental
PhenoxypropazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Phenoxypropazine.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Phenprobamate.Experimental
PhensuximideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Phensuximide.Approved
PhenterminePhentermine may decrease the sedative and stimulatory activities of Dimenhydrinate.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Dimenhydrinate.Approved, Vet Approved
PiclozotanThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Piclozotan.Investigational
PimavanserinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pimavanserin.Approved, Investigational
PimozideThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Pimozide.Approved
PinazepamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pinazepam.Experimental
PindololThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pipecuronium.Approved
Pipemidic acidThe risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Dimenhydrinate.Experimental
PipotiazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Piritramide.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pirlimycin.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pirlindole.Approved
Piromidic acidThe risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Dimenhydrinate.Experimental
PitolisantThe therapeutic efficacy of Pitolisant can be decreased when used in combination with Dimenhydrinate.Approved, Investigational
PivagabineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pivagabine.Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pizotifen.Approved
PlazomicinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Plazomicin.Approved, Investigational
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Polymyxin B Sulfate.Approved, Vet Approved
PomalidomideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pomalidomide.Approved
PosaconazoleThe risk or severity of QTc prolongation can be increased when Posaconazole is combined with Dimenhydrinate.Approved, Investigational, Vet Approved
PracinostatThe risk or severity of QTc prolongation can be increased when Pracinostat is combined with Dimenhydrinate.Investigational
PramipexoleDimenhydrinate may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Dimenhydrinate can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PridinolThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pridinol.Experimental
PrimaquineThe risk or severity of QTc prolongation can be increased when Primaquine is combined with Dimenhydrinate.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Dimenhydrinate.Approved, Vet Approved
ProbucolThe risk or severity of QTc prolongation can be increased when Probucol is combined with Dimenhydrinate.Approved, Investigational
ProcainamideThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Procarbazine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dimenhydrinate.Approved, Vet Approved
ProgabideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Progabide.Approved, Investigational
PromazineThe risk or severity of QTc prolongation can be increased when Promazine is combined with Dimenhydrinate.Approved, Vet Approved
PromethazineThe risk or severity of QTc prolongation can be increased when Promethazine is combined with Dimenhydrinate.Approved, Investigational
PropafenoneThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Dimenhydrinate.Approved
PropanididThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Propanidid.Experimental
PropericiazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Propericiazine.Approved, Investigational
PropiomazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Propiomazine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Propiopromazine.Vet Approved
PropofolThe risk or severity of QTc prolongation can be increased when Propofol is combined with Dimenhydrinate.Approved, Investigational, Vet Approved
ProthipendylThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of QTc prolongation can be increased when Protriptyline is combined with Dimenhydrinate.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Proxibarbal.Experimental
PrulifloxacinThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Dimenhydrinate.Investigational
PRX-08066The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with PRX-08066.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative and stimulatory activities of Dimenhydrinate.Approved
PsilocybineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Psilocybine.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Puromycin.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pyrantel.Approved, Vet Approved
PyrithyldioneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pyrithyldione.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Dimenhydrinate.Approved, Illicit
QuetiapineThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Quetiapine.Approved
QuinidineThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Quinidine.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Quinine.Approved
QuinupramineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Quinupramine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ramelteon.Approved, Investigational
RamosetronThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ramosetron.Approved, Investigational
RanolazineThe risk or severity of QTc prolongation can be increased when Ranolazine is combined with Dimenhydrinate.Approved, Investigational
RapacuroniumThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Rasagiline.Approved
ReboxetineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Reboxetine.Approved, Investigational
RemacemideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Remacemide.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dimenhydrinate.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Remoxipride.Approved, Withdrawn
RenzaprideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Renzapride.Investigational
RepinotanThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Repinotan.Investigational
ReposalThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Reposal.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dimenhydrinate.Approved, Investigational
RibociclibThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Ribociclib.Approved, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ribostamycin.Approved, Investigational
RicolinostatThe risk or severity of QTc prolongation can be increased when Ricolinostat is combined with Dimenhydrinate.Investigational
RilpivirineThe risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Dimenhydrinate.Approved
RiluzoleThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Riluzole.Approved, Investigational
RisperidoneThe risk or severity of QTc prolongation can be increased when Risperidone is combined with Dimenhydrinate.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ritanserin.Investigational
RitobegronRitobegron may decrease the sedative and stimulatory activities of Dimenhydrinate.Investigational
RitonavirThe risk or severity of QTc prolongation can be increased when Ritonavir is combined with Dimenhydrinate.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Rizatriptan.Approved
RocuroniumThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Rocuronium.Approved
RolipramThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Rolipram.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Rolitetracycline.Approved
RomidepsinThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Romidepsin.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Romifidine.Vet Approved
RopiniroleDimenhydrinate may increase the sedative activities of Ropinirole.Approved, Investigational
RosoxacinThe risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Dimenhydrinate.Approved, Investigational
RotigotineDimenhydrinate may increase the sedative activities of Rotigotine.Approved
RoxithromycinThe risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Dimenhydrinate.Approved, Investigational, Withdrawn
RP-5063The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with RP-5063.Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dimenhydrinate.Approved
RufloxacinThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Dimenhydrinate.Experimental
RupatadineThe risk or severity of QTc prolongation can be increased when Rupatadine is combined with Dimenhydrinate.Approved
SafinamideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Safrazine.Withdrawn
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Dimenhydrinate.Approved, Vet Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Dimenhydrinate.Approved
SaquinavirThe risk or severity of QTc prolongation can be increased when Saquinavir is combined with Dimenhydrinate.Approved, Investigational
SarafloxacinThe risk or severity of QTc prolongation can be increased when Sarafloxacin is combined with Dimenhydrinate.Vet Approved, Withdrawn
SaredutantThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Saredutant.Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Sarpogrelate.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dimenhydrinate.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dimenhydrinate.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Selegiline.Approved, Investigational, Vet Approved
SerotoninThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Serotonin.Investigational, Nutraceutical
SertindoleThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Sertraline.Approved
SevofluraneThe risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Dimenhydrinate.Approved, Vet Approved
SibutramineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Sibutramine.Approved, Illicit, Investigational, Withdrawn
SisomicinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Sisomicin.Investigational
SitafloxacinThe risk or severity of QTc prolongation can be increased when Sitafloxacin is combined with Dimenhydrinate.Experimental, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved
SolifenacinThe risk or severity of QTc prolongation can be increased when Solifenacin is combined with Dimenhydrinate.Approved
SorafenibThe risk or severity of QTc prolongation can be increased when Sorafenib is combined with Dimenhydrinate.Approved, Investigational
SotalolThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Sotalol.Approved
SparfloxacinThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Sparfloxacin.Approved, Investigational
St. John's WortThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Stiripentol.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Streptomycin.Approved, Vet Approved
StyramateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Styramate.Experimental
SuccinylcholineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dimenhydrinate.Approved, Investigational
SulfamethoxazoleThe risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Dimenhydrinate.Approved
SulfisoxazoleThe risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Dimenhydrinate.Approved, Vet Approved
SulpirideThe risk or severity of QTc prolongation can be increased when Sulpiride is combined with Dimenhydrinate.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Sulthiame.Experimental
SultoprideThe risk or severity of QTc prolongation can be increased when Sultopride is combined with Dimenhydrinate.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Sumatriptan.Approved, Investigational
SunitinibThe risk or severity of QTc prolongation can be increased when Sunitinib is combined with Dimenhydrinate.Approved, Investigational
SuvorexantDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TalbutalThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Talbutal.Approved, Illicit
TalopramThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Talopram.Experimental
TamoxifenThe risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Dimenhydrinate.Approved
TandospironeThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tandospirone.Investigational
TandutinibThe risk or severity of QTc prolongation can be increased when Tandutinib is combined with Dimenhydrinate.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tasimelteon.Approved, Investigational
TD-8954The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with TD-8954.Investigational
Technetium Tc-99m ciprofloxacinThe risk or severity of QTc prolongation can be increased when Technetium Tc-99m ciprofloxacin is combined with Dimenhydrinate.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tedizolid phosphate.Approved
TegaserodThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tegaserod.Approved, Investigational, Withdrawn
TelavancinThe risk or severity of QTc prolongation can be increased when Telavancin is combined with Dimenhydrinate.Approved
TelithromycinThe risk or severity of QTc prolongation can be increased when Telithromycin is combined with Dimenhydrinate.Approved
TemafloxacinThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Temafloxacin.Withdrawn
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dimenhydrinate.Approved, Investigational
TerbutalineThe risk or severity of QTc prolongation can be increased when Terbutaline is combined with Dimenhydrinate.Approved
TerfenadineThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Terfenadine.Approved, Withdrawn
TerlipressinThe risk or severity of QTc prolongation can be increased when Terlipressin is combined with Dimenhydrinate.Approved, Investigational
TerodilineThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Terodiline.Experimental
TetrabenazineThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Tetrabenazine.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tetracycline.Approved, Vet Approved
TetrahydrocannabivarinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tetrahydrocannabivarin.Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tetrahydropalmatine.Investigational
TetrazepamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tetrazepam.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tetrodotoxin.Investigational
ThalidomideDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Thiamylal.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Thiazinam.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Thiethylperazine.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Thiocolchicoside.Approved, Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Thioproperazine.Approved
ThioridazineThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of QTc prolongation can be increased when Thiothixene is combined with Dimenhydrinate.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Dimenhydrinate.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tianeptine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tiapride.Approved, Investigational
TigecyclineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tigecycline.Approved
TiletamineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tilidine.Experimental
TizanidineThe risk or severity of QTc prolongation can be increased when Tizanidine is combined with Dimenhydrinate.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tobramycin.Approved, Investigational
TofisopamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tofisopam.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dimenhydrinate.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Toloxatone.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tolperisone.Approved, Investigational
TolterodineThe risk or severity of QTc prolongation can be increased when Tolterodine is combined with Dimenhydrinate.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Dimenhydrinate.Approved
ToremifeneThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dimenhydrinate.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tramiprosate.Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Trazodone.Approved, Investigational
TreprostinilThe risk or severity of QTc prolongation can be increased when Treprostinil is combined with Dimenhydrinate.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Dimenhydrinate.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Trichloroethylene.Approved
TriclofosThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Triclofos.Withdrawn
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dimenhydrinate.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Triflupromazine.Approved, Vet Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Trimethadione.Approved
TrimethoprimThe risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Dimenhydrinate.Approved, Vet Approved
TrimipramineThe risk or severity of QTc prolongation can be increased when Trimipramine is combined with Dimenhydrinate.Approved
TriprolidineThe risk or severity of QTc prolongation can be increased when Triprolidine is combined with Dimenhydrinate.Approved
TriptorelinThe risk or severity of QTc prolongation can be increased when Triptorelin is combined with Dimenhydrinate.Approved, Vet Approved
TropisetronThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tropisetron.Approved, Investigational
TrovafloxacinThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tubocurarine.Approved
TucidinostatThe risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Dimenhydrinate.Investigational
UrapidilThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Urapidil.Investigational
VabicaserinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Vabicaserin.Investigational
ValerianThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Valerian.Approved, Experimental, Investigational
ValnoctamideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Valnoctamide.Investigational
Valproic AcidThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Valproic Acid.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Valpromide.Experimental
VancomycinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Vancomycin.Approved
VandetanibThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Vandetanib.Approved
VardenafilThe risk or severity of QTc prolongation can be increased when Vardenafil is combined with Dimenhydrinate.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Vecuronium.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Vigabatrin.Approved
VilanterolThe risk or severity of QTc prolongation can be increased when Vilanterol is combined with Dimenhydrinate.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Vilazodone.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Viloxazine.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Vinbarbital.Experimental
VinpocetineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Vinyl ether.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Vinylbital.Experimental
VoriconazoleThe risk or severity of QTc prolongation can be increased when Voriconazole is combined with Dimenhydrinate.Approved, Investigational
VorinostatThe risk or severity of QTc prolongation can be increased when Vorinostat is combined with Dimenhydrinate.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Vortioxetine.Approved, Investigational
WortmanninThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Wortmannin.Experimental
XP19986The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with XP19986.Investigational
XylazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Xylazine.Vet Approved
YKP-1358The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with YKP-1358.Investigational
YohimbineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dimenhydrinate.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Zolmitriptan.Approved, Investigational
ZolpidemDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dimenhydrinate.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Dimenhydrinate.Approved
ZotepineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food.

References

Synthesis Reference

Cusic, J.W.; U.S. Patent 2,499,058; February 28,1950; assigned to G.D. Searle & Co. Cusic, J.W.; U.S. Patent 2,534,813; December 19,1950; assigned to G.D. Searle & Co.

General References
  1. Takeda N, Morita M, Hasegawa S, Horii A, Kubo T, Matsunaga T: Neuropharmacology of motion sickness and emesis. A review. Acta Otolaryngol Suppl. 1993;501:10-5. [PubMed:8447218]
  2. Halpert AG, Olmstead MC, Beninger RJ: Mechanisms and abuse liability of the anti-histamine dimenhydrinate. Neurosci Biobehav Rev. 2002 Jan;26(1):61-7. [PubMed:11835984]
  3. Jaju BP, Wang SC: Effects of diphenhydramine and dimenhydrinate on vestibular neuronal activity of cat: a search for the locus of their antimotion sickness action. J Pharmacol Exp Ther. 1971 Mar;176(3):718-24. [PubMed:4329456]
  4. Spealman RD: Psychomotor stimulant effects of methylxanthines in squirrel monkeys: relation to adenosine antagonism. Psychopharmacology (Berl). 1988;95(1):19-24. [PubMed:3133696]
External Links
Human Metabolome Database
HMDB0015120
KEGG Drug
D00520
PubChem Compound
441281
PubChem Substance
46504881
ChemSpider
10468539
ChEBI
4604
ChEMBL
CHEMBL1200406
Therapeutic Targets Database
DAP000333
PharmGKB
PA449338
Drugs.com
Drugs.com Drug Page
Wikipedia
Dimenhydrinate
AHFS Codes
  • 56:22.08 — Antihistamines
MSDS
Download (72 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentProphylaxis against postoperative nausea and vomiting1
3RecruitingTreatmentVertigo, Peripheral1
4CompletedPreventionProphylaxis against postoperative nausea and vomiting1
4CompletedTreatmentGastroenteritis1
4CompletedTreatmentNausea / Vertigo / Vomiting1
4CompletedTreatmentVertigo, Peripheral1
Not AvailableCompletedTreatmentNausea / Vomiting1

Pharmacoeconomics

Manufacturers
  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia and critical care
  • Watson laboratories inc
  • Wyeth ayerst laboratories
  • Alra laboratories inc
  • Heather drug co inc
  • Nexgen pharma inc
Packagers
  • APP Pharmaceuticals
  • C.O. Truxton Inc.
  • Consolidated Midland Corp.
  • Dispensing Solutions
  • Hospira Inc.
  • Ivax Pharmaceuticals
  • Major Pharmaceuticals
  • Martin Surgical Supply
  • Medisca Inc.
  • Nexgen Pharma Inc.
  • Pfizer Inc.
  • Pharmacia Inc.
  • Prescript Pharmaceuticals
  • Southwood Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral25 mg/1
SolutionOral15 mg
Injection, solutionIntramuscular; Intravenous50 mg/mL
TabletOral50 mg/1
Tablet, film coatedOral50 mg/1
LiquidIntravenous10 mg
LiquidIntramuscular; Intravenous50 mg
SolutionIntramuscular; Intravenous50 mg
LiquidOral15 mg
TabletOral50 mg
TabletOral50.0 mg
Tablet, chewableOral25 mg/1
Tablet, chewableOral50 mg/1
CapsuleOral
Capsule, extended releaseOral75 mg
SuppositoryRectal100 mg
TabletOral15 mg
SolutionIntramuscular50 mg
Tablet, multilayerOral100 mg
SolutionIntravenous10 mg
SuppositoryRectal25 mg
SyrupOral15 mg
Tablet, chewableOral15 mg
Tablet, extended releaseOral75 mg
Tablet, chewableOral50 mg
TabletOral25 mg
CapsuleOral50 mg
Tablet, coatedOral50 mg/1
SyrupOral3 mg
SuppositoryRectal50 mg
Prices
Unit descriptionCostUnit
Dimenhydrinate 50 mg/ml vial5.7USD ml
Dimenhydrinate I.M. 50 mg/ml1.17USD ml
Meclizine 12.5 mg tablet0.62USD tablet
Dramamine less drowsy tablet0.42USD tablet
Dimenhydrinate I.V. 10 mg/ml0.32USD ml
Dramamine 50 mg tablet0.28USD tablet
Novamine 15% iv solution0.09USD ml
Dimenhydrinate 100% powder0.07USD g
Driminate 50 mg tablet0.05USD tablet
Dimenhydrinate 50 mg tablet0.03USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)102.5-104Cusic, J.W.; U.S. Patent 2,499,058; February 28,1950; assigned to G.D. Searle & Co. Cusic, J.W.; U.S. Patent 2,534,813; December 19,1950; assigned to G.D. Searle & Co.
water solubility3000 mg/LMERCK INDEX (1996); approx.
logP-0.39Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00125 mg/mLALOGPS
logP2.67ALOGPS
logP3.65ChemAxon
logS-5.6ALOGPS
pKa (Strongest Basic)8.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area13.67 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity90.94 m3·mol-1ChemAxon
Polarizability30.28 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9975
Blood Brain Barrier+0.8551
Caco-2 permeable+0.5198
P-glycoprotein substrateSubstrate0.7863
P-glycoprotein inhibitor INon-inhibitor0.6923
P-glycoprotein inhibitor IIInhibitor0.6502
Renal organic cation transporterNon-inhibitor0.6507
CYP450 2C9 substrateNon-substrate0.7536
CYP450 2D6 substrateNon-substrate0.8181
CYP450 3A4 substrateSubstrate0.7086
CYP450 1A2 substrateInhibitor0.5287
CYP450 2C9 inhibitorNon-inhibitor0.6308
CYP450 2D6 inhibitorNon-inhibitor0.8589
CYP450 2C19 inhibitorNon-inhibitor0.5817
CYP450 3A4 inhibitorNon-inhibitor0.9028
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5738
Ames testNon AMES toxic0.5629
CarcinogenicityNon-carcinogens0.7548
BiodegradationNot ready biodegradable0.8211
Rat acute toxicity2.4087 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5364
hERG inhibition (predictor II)Inhibitor0.5405
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Xanthines / 6-oxopurines / Alkaloids and derivatives / Benzylethers / Pyrimidones / Aryl chlorides / Vinylogous amides / Heteroaromatic compounds / Imidazoles / Ureas
show 9 more
Substituents
Diphenylmethane / Xanthine / 6-oxopurine / Purinone / Purine / Benzylether / Alkaloid or derivatives / Imidazopyrimidine / Pyrimidone / Aryl chloride
show 26 more
Molecular Framework
Not Available
External Descriptors
organic salt (CHEBI:4604)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Halpert AG, Olmstead MC, Beninger RJ: Mechanisms and abuse liability of the anti-histamine dimenhydrinate. Neurosci Biobehav Rev. 2002 Jan;26(1):61-7. [PubMed:11835984]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:47